Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence.

Abstract Alzheimer’s disease (AD) is characterized by non-linear, genetic-drivenpathophysiological dynamics with high heterogeneity in biological alterations and disease spatial-temporal progression. Human in-vivo and post-mortem studies point out a failure of multi-level biological networks underlying AD pathophysiology, including proteostasis (amyloid-β and tau), synaptic homeostasis, inflammatory and immune responses, lipid and energy metabolism, oxidative stress. Therefore, a holistic, systems-level approach is needed to fully capture AD multi-faceted pathophysiology. Omics sciences – genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics – embedded in the systems biology (SB) theoretical and computational framework can generate explainable readouts describing the entire biological continuum of a disease. Such path in Neurology is encouraged by the promising results of omics sciences and SB approaches in Oncology, where stage-driven pathway-based therapies have been developed in line with the precision medicine paradigm. Multi-omics data integrated in SB network approaches will help detect and chart AD upstream pathomechanistic alterations and downstream molecular effects occurring in preclinical stages. Finally, integrating omics and neuroimaging data – i.e., neuroimaging-omics – will identify multi-dimensional biological signatures essential to track the clinical-biological trajectories, at the subpopulation or even individual level.